Chemoprevention with dutasteride (a 5-alpha reductase inhibitor or 5-ARI), given at a dose of 0.5 mg daily, reduced the risk of incident prostate cancer detected on biopsy and improved outcomes related to benign prostatic hyperplasia, according to the results published in the April 1, 2010, edition of the New England Journal of Medicine.
Chemoprevention with dutasteride (a 5-alpha reductase inhibitoror 5-ARI), given at a dose of 0.5 mg daily, reduced the risk of incident prostate cancer detected on biopsy and improved outcomes related to benign prostatic hyperplasia, according to the results published in the April 1, 2010, edition of the New England Journal of Medicine.
The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was a 4-year, multicenter, randomized, double-blind, placebo-controlled, parallel group study that included men aged 50 to 75 with a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng/mL and at least 1 negative prostate biopsy within 6 months before enrollment. Among 6,729 men who underwent a biopsy or prostate surgery, cancer was detected in only 19.9% of men in the dutasteride group, as compared with 25.1% of men in the placebo group, representing a relative risk reduction with dutasteride of 22.8% (95% CI, 15.2–29.8) and an absolute risk reduction of 5.1% over the 4-year study period (P<.001). Furthermore, dutasteride therapy resulted in a reduction in the rate of acute urinary retention (1.6% vs 6.7%, a 77.3% relative risk reduction), as compared with placebo.
Recently, the American Society of Clinical Oncology (ASCO) and American Urological Association (AUA) released clinical practice guidelines supporting the use of 5-ARIs for chemoprevention of prostate cancer in asymptomatic men with a PSA ≤3.0 ng/mL who are regularly screened with PSA or are anticipating undergoing annual PSA screening.
Dr Walsh further cautioned that the use of these drugs for prevention may be risky. "Because PSA levels are suppressed, men may have a false sense of security, and if prostate cancer ever develops, the diagnosis may be delayed until they have high-grade disease that may be difficult to cure," Dr Walsh wrote.
Dr Walsh's concerns are not unsupported. During follow-up years 3 and 4 of REDUCE, there were 12 highly aggressive tumors with a Gleason score of 8 to 10 (the Gleason score is the sum of the 2 most common grades of prostate tumor, each of which is graded on a scale of 1 to 5, with 5 most aggressive) in the dutasteride group, as compared with only 1 in the placebo group (P=.003). Similar concerns were found in a recent meta-analysis, which was used as the basis for current clinical treatment guidelines.
ASCO and AUA note in their jointly published guideline document, "Although the majority of the Panel judged that the observed higher incidence of high-grade (Gleason score 8 to 10) cancer [with chemoprevention] ... is likely due to confounding factors, the increased incidence of high-grade cancer as a result of induction by the drug cannot be excluded with certainty."
SOURCES
1. Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–1202.
2. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med. 2010;362:1237–1238.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.